Share on StockTwits

Analysts at Standpoint Research upped their price objective on shares of United Therapeutics (NASDAQ:UTHR) from $118.00 to $140.00 in a research report issued to clients and investors on Friday. The firm currently has a “buy” rating on the stock. Standpoint Research’s target price suggests a potential upside of 52.69% from the company’s current price.

In other United Therapeutics news, CFO John Maxim Ferrari sold 10,000 shares of the company’s stock in a transaction dated Thursday, August 21st. The stock was sold at an average price of $93.75, for a total transaction of $937,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of United Therapeutics (NASDAQ:UTHR) traded up 26.87% during mid-day trading on Friday, hitting $116.33. The stock had a trading volume of 4,159,246 shares. United Therapeutics has a 52-week low of $70.68 and a 52-week high of $116.65. The stock has a 50-day moving average of $91.63 and a 200-day moving average of $95.41. The company has a market cap of $5.499 billion and a P/E ratio of 17.72.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Tuesday, July 29th. The company reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter in the previous year, the company posted $1.52 earnings per share. The company’s revenue for the quarter was up 15.0% on a year-over-year basis. Analysts expect that United Therapeutics will post $8.55 EPS for the current fiscal year.

UTHR has been the subject of a number of other recent research reports. Analysts at Zacks upgraded shares of United Therapeutics from a “neutral” rating to an “outperform” rating in a research note on Thursday, August 21st. They now have a $112.00 price target on the stock. Separately, analysts at Wedbush raised their price target on shares of United Therapeutics from $119.00 to $133.00 in a research note on Thursday, July 31st. Finally, analysts at RBC Capital raised their price target on shares of United Therapeutics from $90.00 to $93.00 in a research note on Thursday, July 31st. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $104.87.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.